WO2004020668A3 - Method for treating synovial sarcoma - Google Patents

Method for treating synovial sarcoma Download PDF

Info

Publication number
WO2004020668A3
WO2004020668A3 PCT/JP2003/010591 JP0310591W WO2004020668A3 WO 2004020668 A3 WO2004020668 A3 WO 2004020668A3 JP 0310591 W JP0310591 W JP 0310591W WO 2004020668 A3 WO2004020668 A3 WO 2004020668A3
Authority
WO
WIPO (PCT)
Prior art keywords
synovial sarcoma
treating
subject
disclosed
methods
Prior art date
Application number
PCT/JP2003/010591
Other languages
French (fr)
Other versions
WO2004020668A2 (en
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Original Assignee
Oncotherapy Science Inc
Japan Government
Yusuke Nakamura
Toyomasa Katagiri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Japan Government, Yusuke Nakamura, Toyomasa Katagiri filed Critical Oncotherapy Science Inc
Priority to AU2003256079A priority Critical patent/AU2003256079A1/en
Publication of WO2004020668A2 publication Critical patent/WO2004020668A2/en
Publication of WO2004020668A3 publication Critical patent/WO2004020668A3/en
Priority to US11/067,231 priority patent/US7803370B2/en
Priority to US12/769,599 priority patent/US8697068B2/en
Priority to US13/918,599 priority patent/US8846038B2/en
Priority to US14/447,122 priority patent/US9540447B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject, comprising administering to the subject an effective amount of an antibody against FZD10 protein or a fragment thereof is provided.
PCT/JP2003/010591 2002-08-30 2003-08-21 Method for treating synovial sarcoma WO2004020668A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003256079A AU2003256079A1 (en) 2002-08-30 2003-08-21 Method for treating synovial sarcoma
US11/067,231 US7803370B2 (en) 2002-08-30 2005-02-28 Method for treating synovial sarcoma
US12/769,599 US8697068B2 (en) 2002-08-30 2010-04-28 Method for treating synovial sarcoma
US13/918,599 US8846038B2 (en) 2002-08-30 2013-06-14 Method for treating synovial sarcoma
US14/447,122 US9540447B2 (en) 2002-08-30 2014-07-30 Method for treating synovial sarcoma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40750602P 2002-08-30 2002-08-30
US60/407,506 2002-08-30
US48619503P 2003-07-11 2003-07-11
US60/486,195 2003-07-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/002144 Continuation-In-Part WO2005004912A1 (en) 2002-08-30 2004-02-24 Method for treating synovial sarcoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/067,231 Continuation-In-Part US7803370B2 (en) 2002-08-30 2005-02-28 Method for treating synovial sarcoma

Publications (2)

Publication Number Publication Date
WO2004020668A2 WO2004020668A2 (en) 2004-03-11
WO2004020668A3 true WO2004020668A3 (en) 2004-06-17

Family

ID=31981517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/010591 WO2004020668A2 (en) 2002-08-30 2003-08-21 Method for treating synovial sarcoma

Country Status (2)

Country Link
AU (1) AU2003256079A1 (en)
WO (1) WO2004020668A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
JP2008509076A (en) * 2004-08-05 2008-03-27 国立大学法人 東京大学 Method for treating synovial sarcoma using siRNA against FZD10
DE102004050620A1 (en) 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoclonal antibody against Frizzled receptors
DK2500360T3 (en) 2005-10-31 2015-10-26 Oncomed Pharm Inc Compositions and methods for the diagnosis and treatment of cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
KR20090080082A (en) * 2006-11-14 2009-07-23 노파르티스 아게 Methods of treating, diagnosing or detecting cancer
CN105079805A (en) 2008-09-26 2015-11-25 昂考梅德药品有限公司 Frizzled-binding agents and uses thereof
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
EP2552953B1 (en) 2010-04-01 2017-05-17 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP3281640A1 (en) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
JP2016510411A (en) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with WNT pathway inhibitors
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002641A2 (en) * 1994-07-19 1996-02-01 Cancer Research Campaign Technology Limited Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma
WO2001074405A1 (en) * 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
WO2002016620A2 (en) * 2000-08-19 2002-02-28 Axordia Limited Modulation of stem cell differentiation
WO2002055705A2 (en) * 2001-01-11 2002-07-18 Curagen Corp Proteins and nucleic acids encoding same
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002092635A2 (en) * 2001-05-01 2002-11-21 The Regents Of The University Of California Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2003004045A2 (en) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002641A2 (en) * 1994-07-19 1996-02-01 Cancer Research Campaign Technology Limited Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma
WO2001074405A1 (en) * 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
WO2002016620A2 (en) * 2000-08-19 2002-02-28 Axordia Limited Modulation of stem cell differentiation
WO2002055705A2 (en) * 2001-01-11 2002-07-18 Curagen Corp Proteins and nucleic acids encoding same
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002092635A2 (en) * 2001-05-01 2002-11-21 The Regents Of The University Of California Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2003004045A2 (en) * 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KÄMÄRÄINEN M ET AL: "Epithelial expression of glycodelin in biphasic synovial sarcomas.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 18 MAY 1998, vol. 76, no. 4, 18 May 1998 (1998-05-18), pages 487 - 490, XP001174121, ISSN: 0020-7136 *
NAGAYAMA SATOSHI ET AL: "Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray.", CANCER RESEARCH. UNITED STATES 15 OCT 2002, vol. 62, no. 20, 15 October 2002 (2002-10-15), pages 5859 - 5866, XP002262587, ISSN: 0008-5472 *
TAMBORINI E ET AL: "c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases.", BRITISH JOURNAL OF CANCER. SCOTLAND 3 AUG 2001, vol. 85, no. 3, 3 August 2001 (2001-08-03), pages 405 - 411, XP002262586, ISSN: 0007-0920 *
TERASAKI HARUMI ET AL: "Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - beta-catenin - TCF signaling pathway", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 9, no. 2, February 2002 (2002-02-01), pages 107 - 112, XP002262585, ISSN: 1107-3756 *

Also Published As

Publication number Publication date
AU2003256079A8 (en) 2004-03-19
AU2003256079A1 (en) 2004-03-19
WO2004020668A2 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004020668A3 (en) Method for treating synovial sarcoma
KR101155294B1 (en) Antibodies that immunospecifically bind to BLyS
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
BR9407047A (en) Process for separating a protein from an aqueous protein solution
ATE545658T1 (en) METHOD FOR TREATING SYNOVIAL SARCOMA
WO2003007803A3 (en) Methods for diagnosing and treating alzheimer's disease and parkinson's disease
WO2006059247A3 (en) VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
WO2001079561A3 (en) Alpha-2 adrenergic receptor polymorphisms
DE60025008D1 (en) DETERMINATION OF ADRENOMEDULLIN-BINDING PROTEINS
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
AU1855401A (en) Screening method for candidate drugs
WO2002077609A3 (en) Identification of compounds for the treatment or prevention of proliferative diseases
WO1999066075A3 (en) Diagnostic method based on quantification of extramitochondrial dna
WO2004074505A3 (en) Method for determining functional sites in a protein
WO2000006185A3 (en) Methods of using lanreotide, a somatostatin analogue
SE0300959D0 (en) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
WO2001040291A3 (en) Proteins and nucleic acids encoding the same
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2001063293A8 (en) Diagnosis and treatment of schizophrenia
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11067231

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP